PowerPoint Presentation INTRODUCTION RESULTS METHODS REFERENCES CONCLUSIONS CLINICAL IMPLICATIONS Baseline; IGA 4 Week 12; IGA 1 14-year-old White Male Chest Back Baseline; IGA 3 Week 12; IGA 1 13-year-old Hispanic Female Chest Back Marked Truncal Acne Response to Sarecycline Monotherapy in Different Ethnicities Angela Yen Moore1,2, Stephen Moore1,3, Luke Moore1, Ayman Grada4, Stephen K Tyring3 1Arlington Research Center, Arlington, TX, USA; 2Baylor University Medical Center, Dallas, TX, USA 3Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA; 4Grada Dermatology Research LLC, Chesterbrook, PA, USA ▪ 60-70% of patients present with acne on the trunk.1 ▪ Since severity of truncal acne does not correlate with severity of facial acne, the psychosocial burden and physical pain and bleeding of truncal acne cannot be underestimated. 2 ▪ Oral antibiotics are the mainstay treatment for moderate-to-severe acne vulgaris. ▪ Sarecycline, a narrow-spectrum tetracycline-class drug, is FDA-approved for moderate-to-severe acne vulgaris in patients 9 years of age and older. ▪ Sarecycline exhibits potent anti-inflammatory activity and activity against C. acnes but reduced activity against Gram-negative bacteria commonly found in the gut; these characteristics may contribute to its low potential for antibiotic resistance and favorable safety and tolerability profile. 3 ▪ Significant improvement in truncal acne, using IGA assessments, was reported with sarecycline in Phase 3 clinical trials. 4,5 ▪ We present 2 patients treated with sarecycline monotherapy for 3 months. ▪ At baseline, weeks 3, 6, 9 and 12, we assessed IGA scores and lesion counts change of the trunk. Baseline Data Demographics Skin Phototype Truncal IGA Truncal lesion count* Facial lesion count* 14 yo White male 2 4 47 8 13 yo Hispanic female 4 3 29 28 * Inflammatory lesions (papules and pustules) Inflammatory Lesion Count Reduction Demographics Baseline 3 Wks 6 Wks 9 Wks 12 Wks 14 yo White male 47 22 (53%) 8 (83%) 1 (98%) 2 (96%) 13 yo Hispanic female 29 16 (45%) 4 (86%) 2 (93%) 3 (90%) ▪ No side effects of special interest for tetracycline-family antibiotics, including nausea, diarrhea, esophagitis, pseudotumor cerebri, blurry or double vision, dizziness, vertigo, or blue-gray pigmentation, were observed. ▪ This case series shows rapid improvement in IGA and reduction inflammatory lesion count with oral sarecycline, and confirms previously reported significant improvement of truncal acne in Phase 3 clinical trials ▪ Sarecycline is an effective narrow-spectrum antibiotic alternative that can be utilized in treating truncal acne, especially when topical agents are challenging for the patients to apply due to surface area and location Disclosures: Research grant from Almirall, LLC. 1. Del Rosso JQ, Stein-Gold L, Lynde C, Tanghetti E, Alexis AF. Truncal Acne: A Neglected Entity. J Drugs Dermatol. 2019;18(12):205-1208. 2. Tan J, Beissert S, Cook-Bolden F, et al. Impact of facial and truncal acne on quality of life: A multi-country population-based survey. JAAD International. 2021;3:102-110. doi:10.1016/j.jdin.2021.03.002 3. Bunick CG, Keri J, Tanaka SK, et al. Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation. Antibiotics (Basel). 2021;10(4):439. doi:10.3390/antibiotics10040439 4. Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5 mg/kg/day is effective for moderate to severe acne vulgaris: Results from two identically designed, phase 3, randomized, double-blind clinical trials. Journal of drugs in dermatology : JDD. 2018;17(9):987-996. 5. Del Rosso JQ, Stein Gold L, Baldwin H, et al. Management of Truncal Acne With Oral Sarecycline: Pooled Results from Two Phase-3 Clinical Trials. J Drugs Dermatol. 2021;20(6):634-640. doi:10.36849/JDD.2021.6204 https://doi.org/10.1016/j.jdin.2021.03.002 https://doi.org/10.3390/antibiotics10040439 https://doi.org/10.36849/JDD.2021.6204